Recent studies showed that agonists of PPARs (PPARα, β, and γ) are protective against brain injury (i.e., ischemic cerebral damage and traumatic brain injury) and neurodegeneration (i.e., Alzheimer's disease and Parkinson's disease) [2, 22–24]. Here, PPARA is linked to early-onset autosomal dominant Alzheimer disease.